AdvanTIG-205: Ociperlimab and Tislelizumab as First-Line Treatment in the Metastatic Setting

Condition: Non-Small Cell Lung Cancer

Sponsor: BeiGene, Ltd.

AdvanTIG-205: A Phase 2, Randomized, Double-blind Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Without Sensitizing EGFR or ALK Mutations who have Received No Previous Treatment for Metastatic Disease

Ociperlimab and Tislelizumab in the first line setting for patients with stage IV squamous or non-squamous non-small cell lung cancer.

For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.